research Enhancing dermatology clinical trials: optimizing sites and strategies for success in India
India is ideal for dermatology trials due to diverse patients and cost-effectiveness.
Search
for
Sort by
Research
330-360 / 1000+ resultsresearch Med Check
Horizant has risks like other seizure drugs, Johnson & Johnson misled about Risperdal, and Quanterix found a possible link between brain oxygen loss and Alzheimer's markers.
research Subjects with mild alopecia benefit from aminexil clinical 5: results of a large international observational study
Aminexil clinical 5 effectively reduces hair loss and is well-tolerated.
research Abstracts
Get head MRI for babies with achondroplasia early, use free immunoglobulin light chains to detect certain neurodevelopmental disorders, and video calls work for speech therapy in patients with facial anomalies.
research Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
research Strategy for Generating Blinded Evidence for Single-Arm Trials with External Controls Using Expert Review of Home Video
A new method uses expert reviews of home videos to objectively assess children's developmental milestones in single-arm trials.
research Reporting on Adverse Clinical Events
Monitoring for adverse effects in clinical treatments is crucial.
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
research Adrenoleukodystrophy: A Rare Case Report
Early diagnosis and genetic counseling are crucial for managing adrenoleukodystrophy.
research Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus
The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.
research Decision letter for "The Need to Analyze Telogen Effluvium and Alopecia Areata Parallelly in Long COVID Studies"
research Development of the AAcQLI : A New Instrument for Assessing Quality of Life in Children With Alopecia Areata
research Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies
Extracellular vesicles show promise for treating diseases but face challenges in development and regulation.
research 708 SIG-1451: A topical anti-inflammatory new chemical entity for atopic dermatitis (AD)
SIG-1451 could be a promising new treatment for atopic dermatitis.
research CONSULTATIVE, PROACTIVE PHYSICAL THERAPY FOR PEOPLE WITH LUPUS: A CASE REPORT
Proactive physical therapy improved mobility, reduced fatigue, and pain in lupus patients.
research Development and testing of a decision board to help clinicians present treatment options to lupus nephritis patients in Brazil
The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.
research Commentary on Clinical Safety and Efficacy of Dual Wavelength Low Level Light Therapy in Androgenetic Alopecia; A Double-Blind Randomized Controlled Study
research All Subcomponents of the Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) are Relevant to Identify and Detect Changes in Skin Activity
All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
research Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.
research Industry Report
The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.
research Performance exploration of multi-gene panels of alopecia areata susceptibility and drug-binding targets
research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial
CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
research Review of the 2024 American Academy of Dermatology (AAD) Annual Meeting
New treatments for skin conditions show promise, especially Coacillium® for hair growth in young people with alopecia areata.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
research The Free Communications of the Eighth Clinical Congress (Virtual) of the Gulf Chapter of the American Association of Clinical Endocrinologists; November 5–7, 2020
I'm sorry, but I can't provide a summary without the content of the document.
research Health-related quality of life in mild-moderate patchy alopecia areata: Results from the first controlled Phase 2 clinical trial in this population with STS01 (dithranol/ProSilic) and challenges for the future
Hair regrowth improved, but quality of life did not.
research Straight hair associated with interferon-alfa plus ribavirin in hepatitis C infection
ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.